EUVIMEDEUVIMED entdecken
Open Access

A Microsimulation Model for Chronic Kidney Disease Progression in Type 2 Diabetes Patients in the United States: Michigan Model for Diabetes–Chronic Kidney Disease Model

Wen Ye iD, Xuemei Ding, Jing Li iD, Rakesh Singh, Ryan Farej, Shihchen Kuo iD, Jay C Elliott, Jason Lott, Chun-Ting Yang, Sheldon X Kong, William H Herman iD

Medical Decision Making · 2026

DOI: 10.1177/0272989x261455313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Decision Making, 2026. Verfasst von Wen Ye und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Disease Progression, Renal Insufficiency, Chronic. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Bayer HealthCare Pharmaceutical Inc., National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To develop and validate a microsimulation model to estimate the health outcomes and costs of chronic kidney disease (CKD) in type 2 diabetes (T2D) to inform health policies and reduce the burden of CKD.

Methods

We developed a comprehensive model for CKD in type 2 diabetes that assesses the impact of risk factors on the progression of urine albumin-to-creatinine ratio and estimated glomerular filtration rate and their impact on stroke, myocardial infarction (MI), congestive heart failure (CHF), end-stage kidney disease (ESKD), and death without dialysis or transplant using individual-level longitudinal data for T2D populations and summary data from published literature. We internally validated the model using data from the Chronic Renal Insufficiency Cohort (CRIC) of patients with T2D and CKD over 7 y and externally validated the model using the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial data over 3 y.

Results

The simulated event rates of ESKD, stroke, MI, CHF, and total mortality and the related 95% confidence intervals included the observed event rates in both the internal and external validation cohorts. Using this new model, we showed that lowering the blood pressure target from 140/90 to 120/80 mm Hg in patients with T2D and CKD was cost-saving at the population level.

Conclusion

The Michigan Model for Diabetes–Chronic Kidney Disease (MMD-CKD) model provides accurate estimates of disease progression in patients with T2D and CKD. Modeling disease progression in this population will facilitate future assessments of the cost-effectiveness of systematic screening and interventions for CKD, which may reduce the health and economic burden of CKD in T2D. This model can also serve as a tool for predicting the clinical outcomes of individual patients with T2D and CKD. MMD-CKD 1.0 R Shiny app and is publicly available ( https://michigandiabetesmodelinggroup.github.io/Software_App ). Highlights We developed and validated a microsimulation model to simulate kidney disease progression, cardiovascular outcomes, mortality, direct medical costs, and quality of life in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This model can be used to evaluate the long-term economic burden of CKD in T2D patients in the United States as well as to assess the costs and benefits associated with specific health policies and interventions. In addition, this model can help inform individual patients of their risk of end-stage kidney disease (ESKD) and cardiovascular events, thereby facilitating shared decision making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Disease ProgressionRenal Insufficiency, ChronicHumansComputer SimulationUnited StatesMichiganRisk FactorsCost-Benefit AnalysisGlomerular Filtration RateKidney Failure, ChronicFemaleCost-Effectiveness AnalysisMaleMiddle Aged

Stichwörter der Autor:innen

cost-effectivenessdirect medical costsend-stage kidney diseasehealth-related quality of life

Autor:innen und Institutionen

  • Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA.
  • Bayer HealthCare Pharmaceuticals Inc. (US), Bayer Boulevard, Whippany, NJ, USA.
  • Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.

ORCID-Profile: Wen Ye, Jing Li, Shihchen Kuo, William H Herman

Förderung

  • NIDDK NIH HHS
  • Bayer HealthCare Pharmaceutical Inc.
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Ye, W., Ding, X., Li, J., Singh, R., Farej, R., Kuo, S., Elliott, J. C., Lott, J., Yang, C. T., Kong, S. X., & Herman, W. H. (2026). A Microsimulation Model for Chronic Kidney Disease Progression in Type 2 Diabetes Patients in the United States: Michigan Model for Diabetes–Chronic Kidney Disease Model. Medical Decision Making. https://doi.org/10.1177/0272989x261455313

Vancouver

Ye W, Ding X, Li J, Singh R, Farej R, Kuo S, et al. A Microsimulation Model for Chronic Kidney Disease Progression in Type 2 Diabetes Patients in the United States: Michigan Model for Diabetes–Chronic Kidney Disease Model. Medical Decision Making. 2026. doi:10.1177/0272989x261455313

BibTeX
@article{Ye2026,
  author = {Ye, Wen and Ding, Xuemei and Li, Jing and Singh, Rakesh and Farej, Ryan and Kuo, Shihchen and Elliott, Jay C and Lott, Jason and Yang, Chun-Ting and Kong, Sheldon X and Herman, William H},
  title = {A Microsimulation Model for Chronic Kidney Disease Progression in Type 2 Diabetes Patients in the United States: Michigan Model for Diabetes–Chronic Kidney Disease Model},
  journal = {Medical Decision Making},
  year = {2026},
  doi = {10.1177/0272989x261455313}
}
Kostenlos starten →